Abstract:Background: Inflammation helps regulate normal growth and tissue repair. Although bone morphogenetic proteins (BMPs) and inflammation are known contributors to abnormal bone formation, how these pathways interact in ossification remains unclear. Methods: We examined this potential link in patients with fibrodysplasia ossificans progressiva (FOP), a genetic condition of progressive heterotopic ossification caused by activating mutations in the Activin A type I receptor (ACVR1/ALK2). FOP patients show exquisite sensitivity to trauma, suggesting that BMP pathway activation may alter immune responses. We studied primary blood, monocyte, and macrophage samples from control and FOP subjects using multiplex cytokine, gene expression, and protein analyses; examined CD14+ primary monocyte and macrophage responses to TLR ligands; and assayed BMP, TGF-β activated kinase 1 (TAK1), and NF-κB pathways. Results: FOP subjects at baseline without clinically evident heterotopic ossification showed increased serum IL-3, IL-7, IL-8, and IL-10. CD14+ primary monocytes treated with the TLR4 activator LPS showed increased CCL5, CCR7, and CXCL10; abnormal cytokine/chemokine secretion; and prolonged activation of the NF-κB pathway. FOP macrophages derived from primary monocytes also showed abnormal cytokine/chemokine secretion, increased TGF-β production, and p38MAPK activation. Surprisingly, SMAD phosphorylation was not significantly changed in the FOP monocytes/macrophages. Conclusions: Abnormal ACVR1 activity causes a proinflammatory state via increased NF-κB and p38MAPK activity. Similar changes may contribute to other types of heterotopic ossification, such as in scleroderma and dermatomyositis; after trauma; or with recombinant BMP-induced bone fusion. Our findings suggest that chronic antiinflammatory treatment may be useful for heterotopic ossification.

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

AAV-Mediated Targeting of the Activin A-ACVR1R206H Signaling in Fibrodysplasia Ossificans Progressiva

Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery

An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva

Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells

The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification

Generation of Fibrodysplasia Ossificans Progressiva and Control Integration Free Ipsc Lines from Periodontal Ligament Fibroblasts.

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva

Promiscuous signaling of ligands via mutant ALK2 in fibrodysplasia ossificans progressiva

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Antisense-oligonucleotide Mediated Exon Skipping in Activin-Receptor-like Kinase 2: Inhibiting the Receptor That is Overactive in Fibrodysplasia Ossificans Progressiva.

Fibrodysplasia ossificans progressiva emerges from obscurity

Towards targeting overactive BMP signaling in Fibrodysplasia Ossificans Progressiva

NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva

Primary cilia mediate skeletogenic BMP and Hedgehog signaling in heterotopic ossification